BridgeBio Pharma (BBIO) financial statements
BridgeBio Pharma reported revenue of $502M in fiscal 2025, up 52.1% a year over 6 years.
Net income was -$725M.
Free cash flow was -$447M, and the company returned $48M in net buybacks.
The diluted share count rose 526% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from BridgeBio Pharma's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $41M | $8M | $70M | $78M | $9M | $222M | $502M |
| Cost of revenue | — | — | — | — | $3M | $3M | $2M | $4M | $21M |
| Gross profit | — | — | — | — | $67M | $74M | $7M | $218M | $481M |
| Research and development | $31M | $140M | $210M | $337M | $451M | $399M | $456M | $506M | $452M |
| Selling, general and admin | $13M | $44M | $94M | $146M | $192M | $143M | $151M | $289M | $531M |
| Operating income | -$44M | -$184M | -$266M | -$474M | -$577M | -$512M | -$607M | -$593M | -$523M |
| Interest expense | $13,000 | $3M | $9M | $37M | $47M | $80M | $81M | $91M | $53M |
| Pre-tax income | $44M | $169M | $289M | $505M | -$586M | -$485M | -$653M | -$542M | -$733M |
| Income tax | — | — | — | — | — | $0 | $0 | $1M | $435,000 |
| Net income | -$31M | -$131M | -$261M | -$449M | -$563M | -$481M | -$643M | -$536M | -$725M |
| EPS (diluted) | -$1.00 | -$2.12 | -$2.48 | -$3.80 | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 |
| Diluted shares | 31M | 62M | 105M | 118M | 144M | 147M | 163M | 186M | 192M |
| Gross margin | — | — | — | — | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% |
| Operating margin | — | — | -656.4% | -5752.0% | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% |
| Net margin | — | — | -642.5% | -5439.7% | -806.9% | -619.7% | -6913.9% | -241.4% | -144.4% |
Balance sheet
Fiscal years, from BridgeBio Pharma's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $92M | $436M | $546M | $607M | $788M | $428M | $376M | $681M | $587M |
| Receivables | — | — | — | — | — | — | $2M | $5M | $139M |
| Inventory | — | — | — | — | — | — | — | $0 | $27M |
| Total current assets | — | $445M | $569M | $643M | $889M | $549M | $478M | $721M | $798M |
| Property, plant and equipment | — | $2M | $6M | $20M | $30M | $15M | $12M | $7M | $5M |
| Total assets | — | $465M | $632M | $704M | $1.0B | $623M | $546M | $919M | $936M |
| Total current liabilities | — | $33M | $60M | $96M | $135M | $121M | $144M | $154M | $288M |
| Long-term debt | — | $55M | $92M | $92M | $431M | $431M | $446M | $437M | — |
| Total liabilities | — | $88M | $156M | $596M | $1.9B | $1.9B | $1.9B | $2.4B | $3.0B |
| Shareholders' equity | $86M | $315M | $408M | $58M | -$870M | -$1.3B | -$1.4B | -$1.5B | -$2.1B |
| Net debt | -$92M | -$382M | -$272M | -$262M | $37M | $54M | $71M | -$244M | -$570M |
Cash flow
Fiscal years, from BridgeBio Pharma's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40M | -$137M | -$254M | -$400M | -$498M | -$419M | -$528M | -$521M | -$446M |
| Capital spending | $464,000 | $2M | $3M | $8M | $13M | $5M | $1M | $933,000 | $1M |
| Free cash flow | -$41M | -$139M | -$256M | -$407M | -$511M | -$424M | -$529M | -$522M | -$447M |
| Stock-based compensation | $2M | $6M | $21M | $58M | $100M | $92M | $109M | $96M | $133M |
| Dividends paid | $1M | — | $997,000 | — | — | — | — | — | — |
| Share buybacks (net) | — | — | — | -$75M | -$200M | $0 | $0 | $0 | -$48M |
| Net borrowing | $4M | -$97,000 | — | $0 | -$124M | -$20M | $0 | -$473M | — |
| Free cash flow margin | — | — | -631.7% | -4936.7% | -733.2% | -546.5% | -5686.6% | -235.1% | -89.0% |
| Dividends per share | $0.04 | — | $0.01 | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BBIO.
Open BBIO in InvestinglyQuestions
What was BridgeBio Pharma's revenue in 2025?
$502M in fiscal 2025, from its 10-K filing.
How much free cash flow does BridgeBio Pharma generate?
-$447M in fiscal 2025 (operating cash flow minus capital spending).
From BridgeBio Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.